

REMARKS

Claims 1-34 are pending in the application. Claims 1-3, 6, 7, 15 and 17 have been amended. Claims 36-42 have been added.

Support for the amendments are as follows. In Claim 1, addition of the phrase "coding region" to modify alleles finds support at page 10, lines 5-7. That the genetic locus is multi-allelic is found generally throughout the specification and in particular at page 14, line 20 through page 16, line 15 which describes the length of the sequence required depending on the number of alleles of the genetic locus. Support for substituting the phrase "non-coding region sequence" for "intron" is found in the Specification at page 10, lines 29-33 which defines the term "intron". Similar amendments to the dependent claims conform the claims to the amended antecedent basis.

Support for the amendments to Claim 7 and the claims which depend on Claim 7 are the same as for Claim 1.

The amendment to Claim 17 and the claims dependent on Claim 17 recite that the RFLP fragment patterns produced in the claims are characteristic of the alleles of the HLA locus. Support for that amendment can be found generally throughout the application and at page 35, line 5 through page 37, line 16, particularly at page 35, lines 23-27.

In Claim 34, that the locus can have at least four alleles is described at page 15, lines 3-9. In Claim 35, that the locus can have at least eight alleles is described at page 15, lines 16-20.

New Claim 36 finds support generally throughout the application. That the non-coding region sequence is not more than about two kilobases in length finds support in the Specification at page 16, lines 16-26. In Claim 37, that the

USSN 07/551,239

- 4 -


A

non-coding region sequence is not more than about one kilobase in length finds support in the Specification at page 16, lines 16-26.

In Claim 38, that the sequence polymorphisms are within five kilobases of a variable exon of the gene finds support in the specification at page 18, lines 9-15. In Claim 39, that the sequence polymorphisms are within two kilobases of a variable exon of the gene finds support in the specification at page 18, lines 9-15. In Claim 40, that the sequence polymorphisms are present in an intron sequence adjacent to a variable exon of the locus finds support in the specification at page 18, lines 18-27. In Claim 41, that an intron adjacent the variable exons for Class I loci is intervening sequence 1, 2, 3 or 4 finds support in the specification at page 43, lines 21-23. In Claim 42, that an intron adjacent the variable exons for Class II loci is intervening sequence 1 or 2 finds support in the specification at page 43, lines 21-23. Therefore, no new matter is added.

Early examination and allowance of this application is respectfully requested. If a telephone conference would expedite prosecution of the above-identified application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



Laura Terlizzi
Attorney For Applicant(s)
Reg. No. 31,307

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C., 20231, on September 23, 1992. Express Mail Receipt No. RB 605 849 706 US

9/23/92
Date of Signature 

USSN 07/551,239

- 5 -